Unlock the publisher's digest free
Roula Khalaf, editor -in -chief of the FT, selects her favorite stories in this weekly newsletter.
GSK will use technologies, including artificial intelligence, to improve its productivity as a means of compensating for the potential financial stroke of American prices in the pharmaceutical sector.
The manufacturer of drugs listed in the United Kingdom said that it was “well positioned” to answer if the Trump administration had decided to hit the industry with prices following a survey on the national security implications for implications of Pharmacy imports.
GSK has identified “productivity initiatives” that could save money, such as the use of technology to improve supply processes and AI to find efficiency gains, according to a person familiar with the problem.
The company also identified “mitigation options” in its supply chain, which could include a double source of ingredients, as well as increased manufacturing in the United States, the company announced because it declared results in the first quarter.
GSK provided tens of billions of dollars in investment in manufacturing and research and development in the United States over the next five years, which has been included in its perspectives, he said.
GSK already has six manufacturing sites in the United States, including an investment of $ 800 million under construction in Pennsylvania which was announced last year. His comments arise after Astrazeneca said on Tuesday Would deepen its manufacturing presence in the United States.
The pharmaceutical industry was excluded from the so-called reciprocal rates announced in early April, but US President Donald Trump said on several occasions that he planned to apply them to the sector to encourage investment in American manufacturing.
In the first quarter, high sales of specialized GSK medicines compensated for a drop in vaccine sales, helping the pharmaceutical company to beat expectations.
Emma Walmsley, general manager of GSK, said that Specialty Medicines, the group's largest company, delivered “solid sales” during the quarter, adding that it was focused on cancer and asthma launches.
“This momentum, as well as the strength of our portfolio and the proven capacity to stimulate the effect of operating lever, underlie our confidence in the advice for the year and our longer-term prospects,” she said.
Total turnover was 7.5 billion sterling pounds in the quarter, greater than the consensual forecast of 7.4 billion pounds sterling and up 4% over one year at constant exchange rates.
Sales of specialized drugs increased by 17% compared to the same period the previous year, but vaccine sales dropped by 6%. AREXVY sales, JAB for the syncytial respiratory virus, fell 57% after an American advisory body recommended that a smaller group of people receive the vaccine.
The basic profit per share was 44.9p, above the 40p analyst's average estimate and up 5% compared to the same period of the previous year.
GSK shares have dropped 12% in the past year. In the latest quarter, GSK launched a rare share buy -back program of 2 billion pounds Sterling and said on Wednesday that it had bought 273 million pounds sterling so far. He declared a 16p dividend for the first quarter and plans to pay a 64P dividend for the full year.
